{"protocolSection":{"identificationModule":{"nctId":"NCT01871805","nctIdAliases":["NCT01588028"],"orgStudyIdInfo":{"id":"NP28761"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib"},"statusModule":{"statusVerifiedDate":"2018-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-10-24","type":"ACTUAL"},"completionDateStruct":{"date":"2017-08-31","type":"ACTUAL"},"studyFirstSubmitDate":"2013-05-28","studyFirstSubmitQcDate":"2013-06-04","studyFirstPostDateStruct":{"date":"2013-06-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-01-14","resultsFirstSubmitQcDate":"2016-01-14","resultsFirstPostDateStruct":{"date":"2016-02-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-07-23","lastUpdatePostDateStruct":{"date":"2018-08-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":134,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Alectinib: Phase I (Dose Escalation)","type":"EXPERIMENTAL","description":"Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.","interventionNames":["Drug: Alectinib"]},{"label":"Alectinib (Phase II: RP2 dose)","type":"EXPERIMENTAL","description":"Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.","interventionNames":["Drug: Alectinib"]}],"interventions":[{"type":"DRUG","name":"Alectinib","description":"Participants will receive alectinib as described in the arm descriptions.","armGroupLabels":["Alectinib (Phase II: RP2 dose)","Alectinib: Phase I (Dose Escalation)"],"otherNames":["CH5424802","RO5424802"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Dose Limiting Toxicities (DLTs): Phase I","description":"The DLTs were defined as any which included Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or Grade 4 neutropenia continuing for greater than equal to (\\>=) 7 consecutive days, non-hematological toxicity of Grade 3 or higher (excluding transient electrolyte abnormalities, diarrhea, nausea, and vomiting that recovers to Grade 2 or lower with appropriate treatment and participants having Grade 2 aspartate transaminase (AST) and/or alanine transaminase (ALT) at baseline must have Grade 3 AST/ALT for 7 days or Grade 4 AST/ALT to be considered a DLT), and adverse events (AEs) that required suspension of treatment for a total of \\>=7 days which the Investigator could not rule out as been related to alectinib.","timeFrame":"Throughout Cycle 1 of Phase I (21 days)"},{"measure":"Recommended Phase II Dose (RP2D): Phase I","description":"RP2D was defined as the highest dose with acceptable toxicity as determined from Phase I of the study.","timeFrame":"Throughout Cycle 1 of Phase I (21 days)"},{"measure":"Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase II","description":"Percentage of participants with objective response as assessed by IRC was defined as the percentage of responders in the response evaluable population, where responders were defined as participants determined to have a best overall response of complete response (CR) or partial response (PR) based on the RECIST v1.1 criteria. CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\\<) 10 millimeter (mm). PR: at least a 30 percent (%) decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. CR and PR were to be confirmed by repeat assessments \\>=4 weeks after initial documentation. Clopper-Pearson method was used to calculate 95% confidence interval (CI).","timeFrame":"Cycle 1 Day 1 up to 194 weeks (assessed at every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter) (1 cycle = 21 days)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase I","description":"Percentage of participants with objective response as assessed by Investigator was defined as the percentage of responders in the response evaluable population, where responders were defined as participants determined to have a best overall response of CR or PR based on the RECIST v1.1 criteria. CR: disappearance of all target and non-TLs and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. CR and PR were to be confirmed by repeat assessments \\>=4 weeks after initial documentation. Clopper-Pearson method was used to calculate 95% CI. Data for this outcome were reported for 'alectinib 600 mg' and 'alectinib other than 600 mg' groups as planned.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Duration of Response (DOR) According to RECIST v1.1 by Investigator: Phase I","description":"DOR was defined for responders (CR or PR) as the time from when response was first documented, to first documented disease progression (according to RECIST v1.1) or death (whichever occurred first). Participants who did not progress or did not die after they had a response were censored at date of their last tumor measurement. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Refer \"Outcome Measure 2\" for the definition of CR and PR. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI. Data for this outcome were reported for 'alectinib 600 mg' and 'alectinib other than 600 mg' groups as planned.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase II","description":"Percentage of participants with objective response as assessed by Investigator was defined as the percentage of responders in the response evaluable population, where responders were defined as participants determined to have a best overall response of CR or PR based on the RECIST v1.1 criteria. CR: disappearance of all target and non-TLs and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. CR and PR were to be confirmed by repeat assessments \\>=4 weeks after initial documentation. Clopper-Pearson method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With Disease Control According to RECIST v1.1 by Investigator: Phase II","description":"Disease control rate assessed according to RECIST v1.1 was defined as the percentage of participants with a best overall response of CR, PR, or stable disease (SD) lasting for at least 12 weeks, after the first dose of alectinib. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters on study. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. CR: disappearance of all target and non-TLs and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. 95% CI for rate was constructed using Clopper-Pearson method.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With Disease Progression According to RECIST v1.1 by IRC or Death : Phase II","description":"Percentage of participants with disease progression according to RECIST v1.1 by IRC is defined as the participants with at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Progression-Free Survival (PFS) According to RECIST v1.1 by IRC: Phase II","description":"PFS was defined as the time between first dose of alectinib and date of first documented disease progression according to RECIST v1.1 or death, whichever occurred first. Participants who have neither progressed nor died at the time of the last clinical cut-off or who lost to follow-up were censored at the date of the last tumor assessment showing no progression of disease either during the study treatment or during follow-up. Participants with no post-baseline assessments were censored at the date of first dose. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With Disease Progression According to RECIST v1.1 by Investigator or Death : Phase II","description":"Percentage of participants with disease progression according to RECIST v1.1 by investigator is defined as the participants with at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"PFS According to RECIST v1.1 by Investigator: Phase II","description":"PFS was defined as the time between first dose of alectinib and date of first documented disease progression according to RECIST v1.1 or death, whichever occurred first. Participants who have neither progressed nor died at the time of the last clinical cut-off or who lost to follow-up were censored at the date of the last tumor assessment showing no progression of disease either during the study treatment or during follow-up. Participants with no post-baseline assessments were censored at the date of first dose. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants Who Died Due to Any Cause: Phase II","timeFrame":"Baseline up to death (any cause) (maximum follow up 284 weeks)"},{"measure":"Overall Survival (OS) Time: Phase II","description":"OS was defined as the time between date of first dose and date of death due to any cause. Participants without an event were censored at the date last known to be alive. Participants without any follow-up information were censored at the date of first dose. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Baseline up to death (any cause) (maximum follow up 284 weeks)"},{"measure":"DOR According to RECIST v1.1 by IRC: Phase II","description":"DOR was defined for responders (CR or PR) as the time from when response was first documented, to first documented disease progression (according to RECIST v1.1) or death (whichever occurred first). Participants who did not progress or did not die after they had a response were censored at date of their last tumor measurement. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Refer \"Outcome Measure 2\" for the definition of CR and PR. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"DOR According to RECIST v1.1 by Investigator: Phase II","description":"DOR was defined for responders (CR or PR) as the time from when response was first documented, to first documented disease progression (according to RECIST v1.1) or death (whichever occurred first). Participants who did not progress or did not die after they had a response were censored at date of their last tumor measurement. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Refer \"Outcome Measure 2\" for the definition of CR and PR. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With Central Nervous System Objective Response (COR) According to RECIST v1.1 by IRC: Phase II","description":"COR rate (CORR) was defined as the percentage of participants who had a CR or PR of the baseline central nervous system (CNS) lesions, based on RECIST v.1.1. CNS responses according to RECIST v1.1 did not have to be confirmed. CR was defined as disappearance of all CNS lesions. PR was defined as \\>=30% decrease in the sum of diameters of measurable CNS lesions (taking as reference the baseline sum of diameters). 95% CI was computed using the Clopper-Pearson method.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With COR According to Response Assessment in Neuro-Oncology (RANO) Criteria by IRC: Phase II","description":"CORR was defined as the percentage of participants who had a CR or PR according to RANO criteria of the baseline CNS lesions. As per RANO criteria, CR was defined as disappearance of all enhancing measurable and non-measurable disease, and no new lesions along with stable or clinically improved status, participants off corticosteroids (or on physiologic replacement doses only) and stable or improved non enhancing T2/FLAIR lesions; PR was defined as 50% or more decrease in sum of the products of the diameters (SPD) of measurable enhancing measurable lesions, no new lesion along with stable or clinically improved status, participants off corticosteroids (or on physiologic replacement doses only) and no progression of non-measurable disease (enhancing and non-enhancing T2/FLAIR lesions. Clopper-Pearson method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"CNS Duration of Response (CDOR) According to RECIST v1.1 by IRC: Phase II","description":"CDOR was defined for CNS responders as the time from the first observation of a CNS response of CR or PR until first observation of CNS progression or death from any cause. An analysis by IRC using RECIST v1.1 was performed. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions. CR was defined as disappearance of all CNS lesions. PR was defined as \\>=30% decrease in the sum of diameters of measurable CNS lesions (taking as reference the baseline sum of diameters). The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"CDOR According to RANO Criteria by IRC: Phase II","description":"CDOR was defined as the time from the first observation of a CNS response of CR or PR according to RANO criteria until first observation of CNS progression or death from any cause. An analysis by RANO criteria was performed. Definitions of CR or PR as per RANO was included in description of Outcome Measure 17. As per RANO criteria, progression was defined as 25% or more increase in SPD of measurable enhancing (measurable) compared to the best response after initiation of therapy or Screening; increase (significant) in non-enhancing T2/FLAIR lesions, not attributable to other non-tumor causes; any new lesions; and clinical deterioration (not attributable to other non-tumor causes and not due to steroid decrease) and clear worsening of neurological status with respect to the previous timepoint. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With CNS Progression According to RECIST v1.1 by IRC: Phase II","description":"CNS disease progression was defined as a new CNS lesion or progression of pre-existing CNS lesions according to RECIST v1.1. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Percentage of Participants With CNS Progression According to RANO Criteria by IRC: Phase II","description":"CNS disease progression was defined as a new CNS lesion or progression of pre-existing CNS lesions according to RANO criteria. As per RANO criteria, progression was defined as 25% or more increase in SPD of measurable enhancing (measurable) compared to the best response after initiation of therapy or Screening; increase (significant) in non-enhancing T2/FLAIR lesions, not attributable to other non-tumor causes; any new lesions; and clinical deterioration (not attributable to other non-tumor causes and not due to steroid decrease).","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)"},{"measure":"Maximum Observed Plasma Concentration (Cmax) After Single Dose of Alectinib: Phase I","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 24, 32 and 48 hours post-dose on Cycle 1 Day -3 (1 cycle = 21 days)"},{"measure":"Cmax After Multiple Dose of Alectinib: Phase I","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8 and 10 hours post-dose on Cycle 2 Day 1 (1 cycle = 21 days)"},{"measure":"Area Under the Plasma Concentration (AUC) Versus Time Curve Extrapolated to Infinity (AUCinf) After Single Dose of Alectinib: Phase I","description":"AUCinf = AUC from time zero (pre-dose) to extrapolated infinite time. It is obtained from AUC (0- t) plus AUC (t-inf).","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 24, 32 and 48 hours post-dose on Cycle 1 Day -3 (1 cycle = 21 days)"},{"measure":"AUC From Time Zero to Last Measurable Concentration (AUClast) After Multiple Dose of Alectinib: Phase I","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8 and 10 hours post-dose on Cycle 2 Day 1 (1 cycle = 21 days)"},{"measure":"Ctrough After Multiple Dose of Alectinib: Phase II","timeFrame":"Pre-dose (0 hour) on Day 1 of Cycles 2, Cycle 3, Cycle 4, Cycle 5 (1 cycle = 21 days)"},{"measure":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II","description":"EORTC QLQ-C30 included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \\[1 'very poor' to 7 'Excellent'\\]). Scores were averaged and transformed to lie between 0-100 scale; for each of the symptom scales, higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below (e.g. Global health status/QoL \\[quality of life\\]) represents absolute data at baseline. QoL=quality of life","timeFrame":"Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)"},{"measure":"Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II","description":"EORTC QLQ-LC13 consisted of 13 questions for dyspnea (3 items) and 10 single items (cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm/shoulder, other pain). Questions used 4-point scale (1 'Not at all' to 4 'Very much'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below represents absolute data at baseline.","timeFrame":"Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed, locally advanced, not amenable to curative therapy, or metastatic NSCLC\n* ALK-rearrangement confirmed by the Food and Drug Administration (FDA) approved test\n* NSCLC that has failed crizotinib treatment\n* Measurable disease as defined by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\\<=) 2\n* Adequate hematologic, hepatic and renal function\n\nExclusion Criteria:\n\n* Prior therapy with ALK inhibitor other than crizotinib\n* Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment\n* History of serious cardiac dysfunction\n* History of or current active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)\n* Clinically significant gastrointestinal abnormality that would affect absorption of the drug\n* Pregnant or lactating women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"University of California Irvine","city":"Irvine","state":"California","zip":"92697","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"UCSD Moores Cancer Center","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Loma Linda Cancer Center","city":"Loma Linda","state":"California","zip":"92354","country":"United States","geoPoint":{"lat":34.04835,"lon":-117.26115}},{"facility":"UCLA","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Univ of Colorado Canc Ctr","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"National Jewish Health","city":"Denver","state":"Colorado","zip":"80206","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Lynn Regional Cancer Center West","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"Florida Hospital Cancer Inst","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"UF Health Orlando","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"H. Lee Moffitt Cancer Center and Research Inst.","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"University of Illinois Cancer Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Monroe Medical Associates; Ingalls Memorial Hosp","city":"Harvey","state":"Illinois","zip":"60426","country":"United States","geoPoint":{"lat":41.61003,"lon":-87.64671}},{"facility":"Massachussets General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Beth Israel Deaconess Medical Center","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana Farber Can Ins","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Newton-Wellesley Hospital","city":"Newton","state":"Massachusetts","zip":"02462","country":"United States","geoPoint":{"lat":42.33704,"lon":-71.20922}},{"facility":"St. Joseph Mercy Hospital; Cancer Care Center.","city":"Ann Arbor","state":"Michigan","zip":"48106","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Wayne State Uni ; Karmanos Cancer Center","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Hackensack Univ Med Ctr","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"Roswell Park Cancer Inst.","city":"Buffalo","state":"New York","zip":"14263","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Memorial Sloan-Kettering Cancer Center","city":"Commack","state":"New York","zip":"11725","country":"United States","geoPoint":{"lat":40.84288,"lon":-73.29289}},{"facility":"Richmond University Medical Center; Pharmacy Department","city":"Staten Island","state":"New York","zip":"10310","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"Wake Forest University Health Sciences","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Gabrail Cancer Center","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"The Ohio State University Comprehensive Cancer Center","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Providence Portland Med Ctr","city":"Portland","state":"Oregon","zip":"97213","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Oregon Health & Science Uni","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"St. Luke's Hospital; Pharmacy Department","city":"Bethlehem","state":"Pennsylvania","zip":"18015","country":"United States","geoPoint":{"lat":40.62593,"lon":-75.37046}},{"facility":"Penn State Hershey Cancer Institute","city":"Hershey","state":"Pennsylvania","zip":"17033","country":"United States","geoPoint":{"lat":40.28592,"lon":-76.65025}},{"facility":"Fox Chase Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Pittsburgh Cancer Pavillion","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"MUSC Hollings Cancer Center","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Center for Biomedical Research LLC","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Texas Oncology-Baylor Sammons Cancer Center","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Virginia Cancer Specialists, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Swedish Cancer Inst.","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"University of Wisconsin","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Cross Cancer Institute","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Lakeridge Health Oshawa; Oncology","city":"Oshawa","state":"Ontario","zip":"L1G 2B9","country":"Canada","geoPoint":{"lat":43.90012,"lon":-78.84957}},{"facility":"McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology","city":"Montreal","state":"Quebec","zip":"H3T 1E2","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"referencesModule":{"references":[{"pmid":"32009824","type":"DERIVED","citation":"Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019 Nov 13;10:125-130. doi: 10.2147/LCTT.S209231. eCollection 2019."},{"pmid":"31706099","type":"DERIVED","citation":"Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Mitry E, Muller B, Bordogna W, Balas B, Morcos PN, Shaw AT. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 Jan;139:22-27. doi: 10.1016/j.lungcan.2019.10.015. Epub 2019 Oct 14."},{"pmid":"29748847","type":"DERIVED","citation":"Morcos PN, Nueesch E, Jaminion F, Guerini E, Hsu JC, Bordogna W, Balas B, Mercier F. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2018 Jul;82(1):129-138. doi: 10.1007/s00280-018-3597-5. Epub 2018 May 10."},{"pmid":"27863201","type":"DERIVED","citation":"Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Dec;34(34):4079-4085. doi: 10.1200/JCO.2016.68.4639. Epub 2016 Oct 31."},{"pmid":"27130468","type":"DERIVED","citation":"Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 Sep;17(5):e77-e94. doi: 10.1016/j.cllc.2016.03.005. Epub 2016 Mar 30."},{"pmid":"26708155","type":"DERIVED","citation":"Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19."},{"pmid":"25153538","type":"DERIVED","citation":"Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 milligrams (mg) alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg twice daily (BID) dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"FG001","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"FG002","title":"Alectinib 600 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"FG003","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"FG004","title":"Alectinib 900 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"FG005","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 150 mg alectinib capsules orally to make a dose of 600 mg BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"periods":[{"title":"Phase I","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Alive in Survival Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]},{"title":"Phase II","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"87"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"87"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"45"}]},{"type":"Alive in Survival Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"29"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"13"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all participants who received any dose of alectinib.","groups":[{"id":"BG000","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"BG001","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"BG002","title":"Alectinib 600 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"BG003","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"BG004","title":"Alectinib 900 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"BG005","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"87"},{"groupId":"BG006","value":"134"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"71"},{"groupId":"BG006","value":"113"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"21"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"48"},{"groupId":"BG006","value":"68"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"66"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Dose Limiting Toxicities (DLTs): Phase I","description":"The DLTs were defined as any which included Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or Grade 4 neutropenia continuing for greater than equal to (\\>=) 7 consecutive days, non-hematological toxicity of Grade 3 or higher (excluding transient electrolyte abnormalities, diarrhea, nausea, and vomiting that recovers to Grade 2 or lower with appropriate treatment and participants having Grade 2 aspartate transaminase (AST) and/or alanine transaminase (ALT) at baseline must have Grade 3 AST/ALT for 7 days or Grade 4 AST/ALT to be considered a DLT), and adverse events (AEs) that required suspension of treatment for a total of \\>=7 days which the Investigator could not rule out as been related to alectinib.","populationDescription":"Phase I safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Throughout Cycle 1 of Phase I (21 days)","groups":[{"id":"OG000","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG002","title":"Alectinib 600 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG003","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG004","title":"Alectinib 900 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]}]},{"type":"PRIMARY","title":"Recommended Phase II Dose (RP2D): Phase I","description":"RP2D was defined as the highest dose with acceptable toxicity as determined from Phase I of the study.","populationDescription":"Phase I safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"mg","timeFrame":"Throughout Cycle 1 of Phase I (21 days)","groups":[{"id":"OG000","title":"Alectinib: Phase I","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 240, 300, 460, 600, 760, or 900 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"600"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase II","description":"Percentage of participants with objective response as assessed by IRC was defined as the percentage of responders in the response evaluable population, where responders were defined as participants determined to have a best overall response of complete response (CR) or partial response (PR) based on the RECIST v1.1 criteria. CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\\<) 10 millimeter (mm). PR: at least a 30 percent (%) decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. CR and PR were to be confirmed by repeat assessments \\>=4 weeks after initial documentation. Clopper-Pearson method was used to calculate 95% confidence interval (CI).","populationDescription":"Phase II Response evaluable (RE) population comprised all Phase II participants with measurable disease at baseline who had a baseline tumor assessment and received at least one dose of alectinib.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Cycle 1 Day 1 up to 194 weeks (assessed at every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.2","lowerLimit":"39.67","upperLimit":"64.60"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0056","pValueComment":"Tests null hypothesis that the response rate is equal to 35% versus the alternative hypothesis that the response rate is not equal to 35%.","statisticalMethod":"Exact Clopper-Pearson CI, 2 sided"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase I","description":"Percentage of participants with objective response as assessed by Investigator was defined as the percentage of responders in the response evaluable population, where responders were defined as participants determined to have a best overall response of CR or PR based on the RECIST v1.1 criteria. CR: disappearance of all target and non-TLs and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. CR and PR were to be confirmed by repeat assessments \\>=4 weeks after initial documentation. Clopper-Pearson method was used to calculate 95% CI. Data for this outcome were reported for 'alectinib 600 mg' and 'alectinib other than 600 mg' groups as planned.","populationDescription":"Phase I RE population comprised all Phase I participants with measurable disease at baseline who had a baseline tumor assessment and received at least one dose of alectinib.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib Other Than 600 mg (Fasted/Fed): Phase I","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 240, 300, 460, 760, or 900 mg on Cycle 1 Day -3 and then received 300, 460, 760, or 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","lowerLimit":"38.57","upperLimit":"90.91"},{"groupId":"OG001","value":"55.9","lowerLimit":"37.89","upperLimit":"72.81"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0251","pValueComment":"Tests null hypothesis that the response rate is equal to 35% versus the alternative hypothesis that the response rate is not equal to 35%.","statisticalMethod":"Exact Clopper-Pearson CI, 2 sided"},{"groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0203","pValueComment":"Tests null hypothesis that the response rate is equal to 35% versus the alternative hypothesis that the response rate is not equal to 35%.","statisticalMethod":"Exact Clopper-Pearson CI, 2 sided"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) According to RECIST v1.1 by Investigator: Phase I","description":"DOR was defined for responders (CR or PR) as the time from when response was first documented, to first documented disease progression (according to RECIST v1.1) or death (whichever occurred first). Participants who did not progress or did not die after they had a response were censored at date of their last tumor measurement. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Refer \"Outcome Measure 2\" for the definition of CR and PR. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI. Data for this outcome were reported for 'alectinib 600 mg' and 'alectinib other than 600 mg' groups as planned.","populationDescription":"Phase I RE population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase I (20/40/150 mg)","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib Other Than 600 mg (Fasted/Fed): Phase I","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 240, 300, 460, 760, or 900 mg on Cycle 1 Day -3 and then received 300, 460, 760, or 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"4.9","upperLimit":"20.9"},{"groupId":"OG001","value":"11.0","lowerLimit":"6.3","upperLimit":"14.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase II","description":"Percentage of participants with objective response as assessed by Investigator was defined as the percentage of responders in the response evaluable population, where responders were defined as participants determined to have a best overall response of CR or PR based on the RECIST v1.1 criteria. CR: disappearance of all target and non-TLs and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. CR and PR were to be confirmed by repeat assessments \\>=4 weeks after initial documentation. Clopper-Pearson method was used to calculate 95% CI.","populationDescription":"Phase II RE population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","lowerLimit":"41.87","upperLimit":"63.67"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0010","pValueComment":"Tests null hypothesis that the response rate is equal to 35% versus the alternative hypothesis that the response rate is not equal to 35%.","statisticalMethod":"Exact Clopper-Pearson CI, 2 sided"}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control According to RECIST v1.1 by Investigator: Phase II","description":"Disease control rate assessed according to RECIST v1.1 was defined as the percentage of participants with a best overall response of CR, PR, or stable disease (SD) lasting for at least 12 weeks, after the first dose of alectinib. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters on study. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. CR: disappearance of all target and non-TLs and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters. 95% CI for rate was constructed using Clopper-Pearson method.","populationDescription":"Phase II RE population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","lowerLimit":"55.75","upperLimit":"76.42"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Progression According to RECIST v1.1 by IRC or Death : Phase II","description":"Percentage of participants with disease progression according to RECIST v1.1 by IRC is defined as the participants with at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"Phase II safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) According to RECIST v1.1 by IRC: Phase II","description":"PFS was defined as the time between first dose of alectinib and date of first documented disease progression according to RECIST v1.1 or death, whichever occurred first. Participants who have neither progressed nor died at the time of the last clinical cut-off or who lost to follow-up were censored at the date of the last tumor assessment showing no progression of disease either during the study treatment or during follow-up. Participants with no post-baseline assessments were censored at the date of first dose. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II safety population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"6.3","upperLimit":"12.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Progression According to RECIST v1.1 by Investigator or Death : Phase II","description":"Percentage of participants with disease progression according to RECIST v1.1 by investigator is defined as the participants with at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"Phase II safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"}]}]}]},{"type":"SECONDARY","title":"PFS According to RECIST v1.1 by Investigator: Phase II","description":"PFS was defined as the time between first dose of alectinib and date of first documented disease progression according to RECIST v1.1 or death, whichever occurred first. Participants who have neither progressed nor died at the time of the last clinical cut-off or who lost to follow-up were censored at the date of the last tumor assessment showing no progression of disease either during the study treatment or during follow-up. Participants with no post-baseline assessments were censored at the date of first dose. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II RE population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"5.5","upperLimit":"12.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died Due to Any Cause: Phase II","populationDescription":"Phase II safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline up to death (any cause) (maximum follow up 284 weeks)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Time: Phase II","description":"OS was defined as the time between date of first dose and date of death due to any cause. Participants without an event were censored at the date last known to be alive. Participants without any follow-up information were censored at the date of first dose. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II safety population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline up to death (any cause) (maximum follow up 284 weeks)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","lowerLimit":"17.2","upperLimit":"NA","comment":"Upper limit of 95% CI was not estimable due to low number of events and longer observation time."}]}]}]},{"type":"SECONDARY","title":"DOR According to RECIST v1.1 by IRC: Phase II","description":"DOR was defined for responders (CR or PR) as the time from when response was first documented, to first documented disease progression (according to RECIST v1.1) or death (whichever occurred first). Participants who did not progress or did not die after they had a response were censored at date of their last tumor measurement. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Refer \"Outcome Measure 2\" for the definition of CR and PR. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II RE population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","lowerLimit":"6.9","upperLimit":"NA","comment":"Upper limit of 95% CI was not estimable due to low number of events and longer observation time."}]}]}]},{"type":"SECONDARY","title":"DOR According to RECIST v1.1 by Investigator: Phase II","description":"DOR was defined for responders (CR or PR) as the time from when response was first documented, to first documented disease progression (according to RECIST v1.1) or death (whichever occurred first). Participants who did not progress or did not die after they had a response were censored at date of their last tumor measurement. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Refer \"Outcome Measure 2\" for the definition of CR and PR. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II RE population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"8.8","upperLimit":"18.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Central Nervous System Objective Response (COR) According to RECIST v1.1 by IRC: Phase II","description":"COR rate (CORR) was defined as the percentage of participants who had a CR or PR of the baseline central nervous system (CNS) lesions, based on RECIST v.1.1. CNS responses according to RECIST v1.1 did not have to be confirmed. CR was defined as disappearance of all CNS lesions. PR was defined as \\>=30% decrease in the sum of diameters of measurable CNS lesions (taking as reference the baseline sum of diameters). 95% CI was computed using the Clopper-Pearson method.","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants with measurable CNS lesions at baseline based on RECIST v1.1 according to IRC.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"47.62","upperLimit":"92.73"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With COR According to Response Assessment in Neuro-Oncology (RANO) Criteria by IRC: Phase II","description":"CORR was defined as the percentage of participants who had a CR or PR according to RANO criteria of the baseline CNS lesions. As per RANO criteria, CR was defined as disappearance of all enhancing measurable and non-measurable disease, and no new lesions along with stable or clinically improved status, participants off corticosteroids (or on physiologic replacement doses only) and stable or improved non enhancing T2/FLAIR lesions; PR was defined as 50% or more decrease in sum of the products of the diameters (SPD) of measurable enhancing measurable lesions, no new lesion along with stable or clinically improved status, participants off corticosteroids (or on physiologic replacement doses only) and no progression of non-measurable disease (enhancing and non-enhancing T2/FLAIR lesions. Clopper-Pearson method was used to calculate 95% CI.","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants with measurable CNS lesions at baseline according to RANO criteria by IRC.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","lowerLimit":"23.38","upperLimit":"83.25"}]}]}]},{"type":"SECONDARY","title":"CNS Duration of Response (CDOR) According to RECIST v1.1 by IRC: Phase II","description":"CDOR was defined for CNS responders as the time from the first observation of a CNS response of CR or PR until first observation of CNS progression or death from any cause. An analysis by IRC using RECIST v1.1 was performed. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions. CR was defined as disappearance of all CNS lesions. PR was defined as \\>=30% decrease in the sum of diameters of measurable CNS lesions (taking as reference the baseline sum of diameters). The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"5.8","upperLimit":"NA","comment":"Upper limit of 95% CI was not estimable due to low number of events and longer observation time."}]}]}]},{"type":"SECONDARY","title":"CDOR According to RANO Criteria by IRC: Phase II","description":"CDOR was defined as the time from the first observation of a CNS response of CR or PR according to RANO criteria until first observation of CNS progression or death from any cause. An analysis by RANO criteria was performed. Definitions of CR or PR as per RANO was included in description of Outcome Measure 17. As per RANO criteria, progression was defined as 25% or more increase in SPD of measurable enhancing (measurable) compared to the best response after initiation of therapy or Screening; increase (significant) in non-enhancing T2/FLAIR lesions, not attributable to other non-tumor causes; any new lesions; and clinical deterioration (not attributable to other non-tumor causes and not due to steroid decrease) and clear worsening of neurological status with respect to the previous timepoint. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"11.1","upperLimit":"NA","comment":"Upper limit of 95% CI was not estimable due to low number of events and longer observation time."}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CNS Progression According to RECIST v1.1 by IRC: Phase II","description":"CNS disease progression was defined as a new CNS lesion or progression of pre-existing CNS lesions according to RECIST v1.1. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"20.59"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CNS Progression According to RANO Criteria by IRC: Phase II","description":"CNS disease progression was defined as a new CNS lesion or progression of pre-existing CNS lesions according to RANO criteria. As per RANO criteria, progression was defined as 25% or more increase in SPD of measurable enhancing (measurable) compared to the best response after initiation of therapy or Screening; increase (significant) in non-enhancing T2/FLAIR lesions, not attributable to other non-tumor causes; any new lesions; and clinical deterioration (not attributable to other non-tumor causes and not due to steroid decrease).","populationDescription":"Data were not estimable due to low number of responders and longer observation time.","reportingStatus":"POSTED","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) After Single Dose of Alectinib: Phase I","populationDescription":"Phase I pharmacokinetic (PK) evaluable population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 24, 32 and 48 hours post-dose on Cycle 1 Day -3 (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 240 mg Once and 300 mg BID (Fasted): Phase I","description":"Participants (in fasting condition) received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib 240 mg Once and 300 mg BID (Fed): Phase I","description":"Participants (in non-fasting condition) received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG002","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG003","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG004","title":"Alectinib 600 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG005","title":"Alectinib 600 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG006","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG007","title":"Alectinib 900 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG008","title":"Alectinib 900 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":"12.4"},{"groupId":"OG001","value":"87.7"},{"groupId":"OG002","value":"45.3","spread":"9.24"},{"groupId":"OG003","value":"142.00","spread":"71.4"},{"groupId":"OG004","value":"158.0","spread":"67.2"},{"groupId":"OG005","value":"186.0","spread":"43.1"},{"groupId":"OG006","value":"257.0","spread":"83.1"},{"groupId":"OG007","value":"186.0","spread":"120.0"},{"groupId":"OG008","value":"295.0","spread":"131.0"}]}]}]},{"type":"SECONDARY","title":"Cmax After Multiple Dose of Alectinib: Phase I","populationDescription":"Phase I PK evaluable population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8 and 10 hours post-dose on Cycle 2 Day 1 (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG002","title":"Alectinib 600 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG003","title":"Alectinib 600 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG004","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG005","title":"Alectinib 900 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG006","title":"Alectinib 900 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":"79.0"},{"groupId":"OG001","value":"618","spread":"165"},{"groupId":"OG002","value":"765","spread":"176"},{"groupId":"OG003","value":"670","spread":"360"},{"groupId":"OG004","value":"733","spread":"98.0"},{"groupId":"OG005","value":"1140","spread":"448"},{"groupId":"OG006","value":"1200","spread":"311"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration (AUC) Versus Time Curve Extrapolated to Infinity (AUCinf) After Single Dose of Alectinib: Phase I","description":"AUCinf = AUC from time zero (pre-dose) to extrapolated infinite time. It is obtained from AUC (0- t) plus AUC (t-inf).","populationDescription":"Phase I PK evaluable population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hour*ng/mL","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 24, 32 and 48 hours post-dose on Cycle 1 Day -3 (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 240 mg Once and 300 mg BID (Fasted): Phase I","description":"Participants (in fasting condition) received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib 240 mg Once and 300 mg BID (Fed): Phase I","description":"Participants (in non-fasting condition) received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG002","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG003","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG004","title":"Alectinib 600 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG005","title":"Alectinib 600 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG006","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG007","title":"Alectinib 900 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG008","title":"Alectinib 900 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1360","spread":"436"},{"groupId":"OG001","value":"858"},{"groupId":"OG002","value":"1030","spread":"481"},{"groupId":"OG003","value":"3280","spread":"2240"},{"groupId":"OG004","value":"3310","spread":"1110"},{"groupId":"OG005","value":"3190","spread":"1510"},{"groupId":"OG006","value":"4090","spread":"1680"},{"groupId":"OG007","value":"3730","spread":"2310"},{"groupId":"OG008","value":"7790","spread":"6210"}]}]}]},{"type":"SECONDARY","title":"AUC From Time Zero to Last Measurable Concentration (AUClast) After Multiple Dose of Alectinib: Phase I","populationDescription":"Phase I PK evaluable population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hour*ng/mL","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8 and 10 hours post-dose on Cycle 2 Day 1 (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG001","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG002","title":"Alectinib 600 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG003","title":"Alectinib 600 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG004","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG005","title":"Alectinib 900 mg (Fed): Phase I (20/40 mg)","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."},{"id":"OG006","title":"Alectinib 900 mg (Fed): Phase I (150 mg)","description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1800","spread":"562"},{"groupId":"OG001","value":"4510","spread":"1700"},{"groupId":"OG002","value":"5970","spread":"1140"},{"groupId":"OG003","value":"5300","spread":"3180"},{"groupId":"OG004","value":"5780","spread":"1020"},{"groupId":"OG005","value":"9800","spread":"4660"},{"groupId":"OG006","value":"9500","spread":"2670"}]}]}]},{"type":"SECONDARY","title":"Ctrough After Multiple Dose of Alectinib: Phase II","populationDescription":"Phase II PK evaluable population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose (0 hour) on Day 1 of Cycles 2, Cycle 3, Cycle 4, Cycle 5 (1 cycle = 21 days)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"473","spread":"277"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"521","spread":"272"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"538","spread":"279"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"538","spread":"226"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II","description":"EORTC QLQ-C30 included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \\[1 'very poor' to 7 'Excellent'\\]). Scores were averaged and transformed to lie between 0-100 scale; for each of the symptom scales, higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below (e.g. Global health status/QoL \\[quality of life\\]) represents absolute data at baseline. QoL=quality of life","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"classes":[{"title":"Global health status/QoL: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.59","spread":"24.27"}]}]},{"title":"Global health status/QoL: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.89","spread":"25.66"}]}]},{"title":"Global health status/QoL: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Global health status/QoL: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.83","spread":"23.41"}]}]},{"title":"Global health status/QoL: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Global health status/QoL: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.65","spread":"23.73"}]}]},{"title":"Global health status/QoL: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Global health status/QoL: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.65","spread":"20.77"}]}]},{"title":"Global health status/QoL: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Global health status/QoL: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.03","spread":"19.57"}]}]},{"title":"Global health status/QoL: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"9.62"}]}]},{"title":"Global health status/QoL: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.28","spread":"20.57"}]}]},{"title":"Global health status/QoL: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"5.89"}]}]},{"title":"Global health status/QoL: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.19","spread":"19.33"}]}]},{"title":"Global health status/QoL: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.42","spread":"12.50"}]}]},{"title":"Global health status/QoL: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.06"}]}]},{"title":"Global health status/QoL: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"17.68"}]}]},{"title":"Global health status/QoL: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.95","spread":"16.86"}]}]},{"title":"Global health status/QoL: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"21.73"}]}]},{"title":"Global health status/QoL: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.28","spread":"19.54"}]}]},{"title":"Global health status/QoL: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Global health status/QoL: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.06","spread":"17.80"}]}]},{"title":"Global health status/QoL: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"15.96"}]}]},{"title":"Global health status/QoL: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"18.12"}]}]},{"title":"Global health status/QoL: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Global health status/QoL: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.32","spread":"16.44"}]}]},{"title":"Global health status/QoL: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Global health status/QoL: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.90","spread":"14.98"}]}]},{"title":"Global health status/QoL: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Global health status/QoL: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"11.79"}]}]},{"title":"Global health status/QoL: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-29.17","spread":"41.25"}]}]},{"title":"Global health status/QoL: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"22.05"}]}]},{"title":"Global health status/QoL: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67"}]}]},{"title":"Global health status/QoL: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67"}]}]},{"title":"Global health status/QoL: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Global health status/QoL: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Global health status/QoL: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.99","spread":"21.27"}]}]},{"title":"Physical functioning: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.96","spread":"24.43"}]}]},{"title":"Physical functioning: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.69","spread":"17.44"}]}]},{"title":"Physical functioning: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Physical functioning: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.20","spread":"22.37"}]}]},{"title":"Physical functioning: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Physical functioning: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.58","spread":"18.23"}]}]},{"title":"Physical functioning: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Physical functioning: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.13","spread":"16.33"}]}]},{"title":"Physical functioning: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"4.71"}]}]},{"title":"Physical functioning: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"17.39"}]}]},{"title":"Physical functioning: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"13.33"}]}]},{"title":"Physical functioning: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.21","spread":"18.10"}]}]},{"title":"Physical functioning: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"14.14"}]}]},{"title":"Physical functioning: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.85","spread":"18.89"}]}]},{"title":"Physical functioning: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"22.11"}]}]},{"title":"Physical functioning: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.25","spread":"16.81"}]}]},{"title":"Physical functioning: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"18.86"}]}]},{"title":"Physical functioning: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"18.32"}]}]},{"title":"Physical functioning: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"20.55"}]}]},{"title":"Physical functioning: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.56","spread":"22.67"}]}]},{"title":"Physical functioning: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"11.55"}]}]},{"title":"Physical functioning: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"19.13"}]}]},{"title":"Physical functioning: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"16.67"}]}]},{"title":"Physical functioning: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.20","spread":"22.70"}]}]},{"title":"Physical functioning: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Physical functioning: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.98","spread":"19.83"}]}]},{"title":"Physical functioning: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Physical functioning: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.08","spread":"21.71"}]}]},{"title":"Physical functioning: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"11.55"}]}]},{"title":"Physical functioning: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"18.32"}]}]},{"title":"Physical functioning: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-26.67","spread":"28.28"}]}]},{"title":"Physical functioning: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"11.55"}]}]},{"title":"Physical functioning: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67"}]}]},{"title":"Physical functioning: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Physical functioning: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Physical functioning: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Physical functioning: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"21.64"}]}]},{"title":"Role functioning: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.86","spread":"34.06"}]}]},{"title":"Role functioning: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.84","spread":"32.00"}]}]},{"title":"Role functioning: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Role functioning: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.65","spread":"32.69"}]}]},{"title":"Role functioning: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Role functioning: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.42","spread":"31.94"}]}]},{"title":"Role functioning: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Role functioning: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.73","spread":"27.85"}]}]},{"title":"Role functioning: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Role functioning: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.83","spread":"24.70"}]}]},{"title":"Role functioning: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"33.33"}]}]},{"title":"Role functioning: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.65","spread":"24.70"}]}]},{"title":"Role functioning: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"0.00"}]}]},{"title":"Role functioning: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","spread":"28.81"}]}]},{"title":"Role functioning Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.83","spread":"15.96"}]}]},{"title":"Role functioning: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.94","spread":"24.54"}]}]},{"title":"Role functioning: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Role functioning: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.29","spread":"24.30"}]}]},{"title":"Role functioning: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.33","spread":"18.26"}]}]},{"title":"Role functioning: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.89","spread":"27.24"}]}]},{"title":"Role functioning: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"9.62"}]}]},{"title":"Role functioning: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"29.90"}]}]},{"title":"Role functioning: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"33.33"}]}]},{"title":"Role functioning: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.97","spread":"27.46"}]}]},{"title":"Role functioning: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Role functioning: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.52","spread":"28.66"}]}]},{"title":"Role functioning: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Role functioning: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":"31.46"}]}]},{"title":"Role functioning: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Role functioning: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"19.42"}]}]},{"title":"Role functioning: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-41.67","spread":"35.36"}]}]},{"title":"Role functioning: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Role functioning: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67"}]}]},{"title":"Role functioning: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Role functioning: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Role functioning: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Role functioning: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.36","spread":"34.47"}]}]},{"title":"Emotional functioning: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.49","spread":"21.40"}]}]},{"title":"Emotional functioning: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.99","spread":"18.75"}]}]},{"title":"Emotional functioning: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.01","spread":"17.04"}]}]},{"title":"Emotional functioning: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.44","spread":"21.17"}]}]},{"title":"Emotional functioning: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.37","spread":"16.75"}]}]},{"title":"Emotional functioning: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"5.89"}]}]},{"title":"Emotional functioning: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.40","spread":"20.34"}]}]},{"title":"Emotional functioning: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-30.56","spread":"26.79"}]}]},{"title":"Emotional functioning: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.89","spread":"19.85"}]}]},{"title":"Emotional functioning: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"5.89"}]}]},{"title":"Emotional functioning: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":"18.12"}]}]},{"title":"Emotional functioning Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"7.98"}]}]},{"title":"Emotional functioning: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.73","spread":"15.23"}]}]},{"title":"Emotional functioning: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Emotional functioning: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.49","spread":"13.40"}]}]},{"title":"Emotional functioning: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"18.07"}]}]},{"title":"Emotional functioning: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"14.12"}]}]},{"title":"Emotional functioning: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"34.69"}]}]},{"title":"Emotional functioning: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.45","spread":"14.52"}]}]},{"title":"Emotional functioning: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"26.35"}]}]},{"title":"Emotional functioning: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.07","spread":"21.43"}]}]},{"title":"Emotional functioning: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"11.79"}]}]},{"title":"Emotional functioning: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.19","spread":"19.77"}]}]},{"title":"Emotional functioning: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"5.89"}]}]},{"title":"Emotional functioning: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"19.79"}]}]},{"title":"Emotional functioning: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"34.69"}]}]},{"title":"Emotional functioning: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"8.26"}]}]},{"title":"Emotional functioning: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.50","spread":"17.68"}]}]},{"title":"Emotional functioning: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Emotional functioning: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Emotional functioning: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":"19.86"}]}]},{"title":"Cognitive functioning: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.85","spread":"24.13"}]}]},{"title":"Cognitive functioning: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"20.76"}]}]},{"title":"Cognitive functioning: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"15.44"}]}]},{"title":"Cognitive functioning: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"15.82"}]}]},{"title":"Cognitive functioning: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.25","spread":"16.34"}]}]},{"title":"Cognitive functioning: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Cognitive functioning: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"17.68"}]}]},{"title":"Cognitive functioning: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-27.78","spread":"25.46"}]}]},{"title":"Cognitive functioning: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.63","spread":"13.16"}]}]},{"title":"Cognitive functioning: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-25.00","spread":"35.36"}]}]},{"title":"Cognitive functioning: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"14.08"}]}]},{"title":"Cognitive functioning Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"51.59"}]}]},{"title":"Cognitive functioning: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.06","spread":"21.58"}]}]},{"title":"Cognitive functioning: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"0.00"}]}]},{"title":"Cognitive functioning: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.53","spread":"22.29"}]}]},{"title":"Cognitive functioning: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"31.18"}]}]},{"title":"Cognitive functioning: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.11","spread":"21.66"}]}]},{"title":"Cognitive functioning: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Cognitive functioning: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.97","spread":"22.23"}]}]},{"title":"Cognitive functioning: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"8.33"}]}]},{"title":"Cognitive functioning: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.97","spread":"20.64"}]}]},{"title":"Cognitive functioning: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Cognitive functioning: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.52","spread":"25.59"}]}]},{"title":"Cognitive functioning: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Cognitive functioning: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.85","spread":"20.59"}]}]},{"title":"Cognitive functioning: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Cognitive functioning: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"15.43"}]}]},{"title":"Cognitive functioning: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Cognitive functioning: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.22","spread":"19.25"}]}]},{"title":"Cognitive functioning: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Cognitive functioning: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"24.45"}]}]},{"title":"Social functioning: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.55","spread":"35.32"}]}]},{"title":"Social functioning: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.20","spread":"23.20"}]}]},{"title":"Social functioning: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.19","spread":"27.93"}]}]},{"title":"Social functioning: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.27","spread":"25.45"}]}]},{"title":"Social functioning: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.54","spread":"26.38"}]}]},{"title":"Social functioning: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Social functioning: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.53","spread":"31.11"}]}]},{"title":"Social functioning: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"25.46"}]}]},{"title":"Social functioning: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.21","spread":"32.35"}]}]},{"title":"Social functioning: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Social functioning: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.80","spread":"30.47"}]}]},{"title":"Social functioning: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"20.97"}]}]},{"title":"Social functioning: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.16","spread":"29.31"}]}]},{"title":"Social functioning: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Social functioning: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.37","spread":"28.53"}]}]},{"title":"Social functioning: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"18.26"}]}]},{"title":"Social functioning: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"25.43"}]}]},{"title":"Social functioning: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Social functioning: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.77","spread":"31.95"}]}]},{"title":"Social functioning: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.83","spread":"25.00"}]}]},{"title":"Social functioning: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.59","spread":"23.80"}]}]},{"title":"Social functioning: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Social functioning: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.70","spread":"23.51"}]}]},{"title":"Social functioning: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Social functioning: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"29.36"}]}]},{"title":"Social functioning: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.78","spread":"25.46"}]}]},{"title":"Social functioning: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.58","spread":"16.52"}]}]},{"title":"Social functioning: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"82.50"}]}]},{"title":"Social functioning: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"16.67"}]}]},{"title":"Social functioning: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Social functioning: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.20","spread":"30.39"}]}]},{"title":"Fatigue: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.57","spread":"27.02"}]}]},{"title":"Fatigue: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.94","spread":"25.70"}]}]},{"title":"Fatigue: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11"}]}]},{"title":"Fatigue: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"27.73"}]}]},{"title":"Fatigue: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Fatigue: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.85","spread":"24.88"}]}]},{"title":"Fatigue: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Fatigue: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.05","spread":"22.06"}]}]},{"title":"Fatigue: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"7.86"}]}]},{"title":"Fatigue: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.97","spread":"23.47"}]}]},{"title":"Fatigue: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.81","spread":"6.42"}]}]},{"title":"Fatigue: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.23","spread":"25.75"}]}]},{"title":"Fatigue: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"7.86"}]}]},{"title":"Fatigue: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.26","spread":"21.50"}]}]},{"title":"Fatigue: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"24.00"}]}]},{"title":"Fatigue: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"22.93"}]}]},{"title":"Fatigue: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"47.14"}]}]},{"title":"Fatigue: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.64","spread":"18.39"}]}]},{"title":"Fatigue: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.44","spread":"16.85"}]}]},{"title":"Fatigue: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.78","spread":"21.27"}]}]},{"title":"Fatigue: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":"23.13"}]}]},{"title":"Fatigue: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.69","spread":"20.07"}]}]},{"title":"Fatigue: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"10.64"}]}]},{"title":"Fatigue: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.21","spread":"22.28"}]}]},{"title":"Fatigue: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"7.86"}]}]},{"title":"Fatigue: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.35","spread":"23.19"}]}]},{"title":"Fatigue: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"7.86"}]}]},{"title":"Fatigue: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.40","spread":"18.62"}]}]},{"title":"Fatigue: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"11.11"}]}]},{"title":"Fatigue: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"17.57"}]}]},{"title":"Fatigue: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"31.43"}]}]},{"title":"Fatigue: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-18.52","spread":"6.42"}]}]},{"title":"Fatigue: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Fatigue: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Fatigue: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Fatigue: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Fatigue: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.85","spread":"21.65"}]}]},{"title":"Nausea and vomiting: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.61","spread":"20.73"}]}]},{"title":"Nausea and vomiting: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.77","spread":"19.63"}]}]},{"title":"Nausea and vomiting: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.02","spread":"21.66"}]}]},{"title":"Nausea and vomiting: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.15","spread":"19.81"}]}]},{"title":"Nausea and vomiting: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.13","spread":"18.48"}]}]},{"title":"Nausea and vomiting: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Nausea and vomiting: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.98","spread":"17.31"}]}]},{"title":"Nausea and vomiting: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"25.46"}]}]},{"title":"Nausea and vomiting: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.46","spread":"17.63"}]}]},{"title":"Nausea and vomiting: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Nausea and vomiting: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.80","spread":"18.47"}]}]},{"title":"Nausea and vomiting: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"8.33"}]}]},{"title":"Nausea and vomiting: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.38","spread":"19.37"}]}]},{"title":"Nausea and vomiting: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"11.79"}]}]},{"title":"Nausea and vomiting: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.85","spread":"19.85"}]}]},{"title":"Nausea and vomiting: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"14.91"}]}]},{"title":"Nausea and vomiting: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"17.29"}]}]},{"title":"Nausea and vomiting: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Nausea and vomiting: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.05","spread":"20.10"}]}]},{"title":"Nausea and vomiting: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Nausea and vomiting: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.80","spread":"19.85"}]}]},{"title":"Nausea and vomiting: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Nausea and vomiting: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"13.26"}]}]},{"title":"Nausea and vomiting: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Nausea and vomiting: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.41","spread":"12.80"}]}]},{"title":"Nausea and vomiting: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"9.62"}]}]},{"title":"Nausea and vomiting: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"13.91"}]}]},{"title":"Nausea and vomiting: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Nausea and vomiting: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"16.67"}]}]},{"title":"Nausea and vomiting: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Nausea and vomiting: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.85","spread":"20.38"}]}]},{"title":"Pain: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.29","spread":"33.63"}]}]},{"title":"Pain: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.50","spread":"33.47"}]}]},{"title":"Pain: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.81","spread":"32.48"}]}]},{"title":"Pain: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.07","spread":"33.55"}]}]},{"title":"Pain: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.35","spread":"31.44"}]}]},{"title":"Pain: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"11.79"}]}]},{"title":"Pain: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"33.37"}]}]},{"title":"Pain: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"9.62"}]}]},{"title":"Pain: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"34.31"}]}]},{"title":"Pain: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Pain: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.09","spread":"23.17"}]}]},{"title":"Pain: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"21.52"}]}]},{"title":"Pain: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.55","spread":"17.81"}]}]},{"title":"Pain: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-25.00","spread":"11.79"}]}]},{"title":"Pain: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"24.86"}]}]},{"title":"Pain: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"39.09"}]}]},{"title":"Pain: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"14.17"}]}]},{"title":"Pain: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"9.62"}]}]},{"title":"Pain: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"23.46"}]}]},{"title":"Pain: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"15.96"}]}]},{"title":"Pain: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.07","spread":"28.62"}]}]},{"title":"Pain: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Pain: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"15.73"}]}]},{"title":"Pain: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"11.79"}]}]},{"title":"Pain: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"19.70"}]}]},{"title":"Pain: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"9.62"}]}]},{"title":"Pain: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"25.20"}]}]},{"title":"Pain: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"35.36"}]}]},{"title":"Pain: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"53.58"}]}]},{"title":"Pain: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.36","spread":"29.92"}]}]},{"title":"Dyspnoea: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"30.86"}]}]},{"title":"Dyspnoea: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.17","spread":"32.96"}]}]},{"title":"Dyspnoea : Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.69","spread":"32.54"}]}]},{"title":"Dyspnoea: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.67","spread":"30.78"}]}]},{"title":"Dyspnoea: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.50","spread":"25.58"}]}]},{"title":"Dyspnoea: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dyspnoea: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.89","spread":"26.21"}]}]},{"title":"Dyspnoea: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Dyspnoea: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.21","spread":"27.37"}]}]},{"title":"Dyspnoea: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Dyspnoea: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.71","spread":"27.40"}]}]},{"title":"Dyspnoea: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"27.22"}]}]},{"title":"Dyspnoea: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"28.63"}]}]},{"title":"Dyspnoea: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dyspnoea: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.29","spread":"23.55"}]}]},{"title":"Dyspnoea: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"14.91"}]}]},{"title":"Dyspnoea: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"22.29"}]}]},{"title":"Dyspnoea: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Dyspnoea: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.97","spread":"24.14"}]}]},{"title":"Dyspnoea: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"16.67"}]}]},{"title":"Dyspnoea: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.45","spread":"32.53"}]}]},{"title":"Dyspnoea: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Dyspnoea: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.76","spread":"21.82"}]}]},{"title":"Dyspnoea: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Dyspnoea: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"23.57"}]}]},{"title":"Dyspnoea: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Dyspnoea: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"29.55"}]}]},{"title":"Dyspnoea: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Dyspnoea: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"38.49"}]}]},{"title":"Dyspnoea: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33"}]}]},{"title":"Dyspnoea: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.63","spread":"33.71"}]}]},{"title":"Insomnia: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.22","spread":"30.82"}]}]},{"title":"Insomnia: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.38","spread":"29.38"}]}]},{"title":"Insomnia: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.26","spread":"34.52"}]}]},{"title":"Insomnia: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.27","spread":"37.86"}]}]},{"title":"Insomnia: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.17","spread":"36.67"}]}]},{"title":"Insomnia: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Insomnia: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.40","spread":"33.29"}]}]},{"title":"Insomnia: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.44","spread":"50.92"}]}]},{"title":"Insomnia: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.77","spread":"40.03"}]}]},{"title":"Insomnia: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.33","spread":"23.57"}]}]},{"title":"Insomnia: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"25.82"}]}]},{"title":"Insomnia: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.67","spread":"31.91"}]}]},{"title":"Insomnia: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.13","spread":"29.77"}]}]},{"title":"Insomnia: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.00","spread":"23.57"}]}]},{"title":"Insomnia: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"28.00"}]}]},{"title":"Insomnia: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.00","spread":"43.46"}]}]},{"title":"Insomnia: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"28.34"}]}]},{"title":"Insomnia: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Insomnia: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.33","spread":"32.89"}]}]},{"title":"Insomnia: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"27.22"}]}]},{"title":"Insomnia: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"26.59"}]}]},{"title":"Insomnia: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Insomnia: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"22.30"}]}]},{"title":"Insomnia: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Insomnia: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"36.00"}]}]},{"title":"Insomnia: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Insomnia: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"30.86"}]}]},{"title":"Insomnia: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Insomnia: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"38.49"}]}]},{"title":"Insomnia: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Insomnia: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":"35.09"}]}]},{"title":"Appetite loss: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.96","spread":"33.16"}]}]},{"title":"Appetite loss: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"30.28"}]}]},{"title":"Appetite loss: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-18.52","spread":"36.44"}]}]},{"title":"Appetite loss: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.26","spread":"33.39"}]}]},{"title":"Appetite loss: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-19.84","spread":"29.50"}]}]},{"title":"Appetite loss: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Appetite loss: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.68","spread":"23.84"}]}]},{"title":"Appetite loss: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-44.44","spread":"19.25"}]}]},{"title":"Appetite loss: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.91","spread":"27.62"}]}]},{"title":"Appetite loss: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-50.00","spread":"23.57"}]}]},{"title":"Appetite loss: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"32.37"}]}]},{"title":"Appetite loss: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"41.94"}]}]},{"title":"Appetite loss: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.83","spread":"34.65"}]}]},{"title":"Appetite loss: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"47.14"}]}]},{"title":"Appetite loss: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-18.75","spread":"32.72"}]}]},{"title":"Appetite loss: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.00","spread":"29.81"}]}]},{"title":"Appetite loss: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.00","spread":"31.07"}]}]},{"title":"Appetite loss: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Appetite loss: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-23.08","spread":"33.69"}]}]},{"title":"Appetite loss: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"33.33"}]}]},{"title":"Appetite loss: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-23.19","spread":"30.87"}]}]},{"title":"Appetite loss: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Appetite loss: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.63","spread":"30.69"}]}]},{"title":"Appetite loss: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Appetite loss: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-25.64","spread":"36.40"}]}]},{"title":"Appetite loss: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Appetite loss: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.83","spread":"39.59"}]}]},{"title":"Appetite loss: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Appetite loss: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-55.56","spread":"50.92"}]}]},{"title":"Appetite loss: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Appetite loss: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.70","spread":"33.72"}]}]},{"title":"Constipation: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.25","spread":"26.38"}]}]},{"title":"Constipation: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.90","spread":"30.68"}]}]},{"title":"Constipation: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Constipation: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"31.33"}]}]},{"title":"Constipation: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33"}]}]},{"title":"Constipation: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.58","spread":"25.84"}]}]},{"title":"Constipation: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Constipation: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"29.81"}]}]},{"title":"Constipation: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"47.14"}]}]},{"title":"Constipation: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":"27.08"}]}]},{"title":"Constipation: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"50.92"}]}]},{"title":"Constipation: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.26","spread":"21.26"}]}]},{"title":"Constipation: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Constipation: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.26","spread":"24.70"}]}]},{"title":"Constipation: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.00","spread":"19.25"}]}]},{"title":"Constipation: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"26.07"}]}]},{"title":"Constipation: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Constipation: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"23.44"}]}]},{"title":"Constipation: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.67","spread":"43.46"}]}]},{"title":"Constipation: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"22.15"}]}]},{"title":"Constipation: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.44","spread":"38.49"}]}]},{"title":"Constipation: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.82","spread":"26.79"}]}]},{"title":"Constipation: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"16.67"}]}]},{"title":"Constipation: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.35","spread":"25.23"}]}]},{"title":"Constipation: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"47.14"}]}]},{"title":"Constipation: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.94","spread":"17.97"}]}]},{"title":"Constipation: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"47.14"}]}]},{"title":"Constipation: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.69","spread":"19.97"}]}]},{"title":"Constipation: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"38.49"}]}]},{"title":"Constipation: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"15.43"}]}]},{"title":"Constipation: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"47.14"}]}]},{"title":"Constipation: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"50.92"}]}]},{"title":"Constipation: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33"}]}]},{"title":"Constipation: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Constipation: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Constipation: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Constipation: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.68","spread":"31.93"}]}]},{"title":"Diarrhoea: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.25","spread":"23.01"}]}]},{"title":"Diarrhoea: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.41","spread":"25.00"}]}]},{"title":"Diarrhoea: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.29","spread":"23.62"}]}]},{"title":"Diarrhoea: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"25.11"}]}]},{"title":"Diarrhoea: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"28.43"}]}]},{"title":"Diarrhoea: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Diarrhoea: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.55","spread":"23.84"}]}]},{"title":"Diarrhoea: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Diarrhoea: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.89","spread":"23.80"}]}]},{"title":"Diarrhoea: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.48","spread":"26.21"}]}]},{"title":"Diarrhoea: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.03","spread":"28.09"}]}]},{"title":"Diarrhoea: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"26.01"}]}]},{"title":"Diarrhoea: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"32.14"}]}]},{"title":"Diarrhoea: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.69","spread":"30.27"}]}]},{"title":"Diarrhoea: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Diarrhoea: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.25","spread":"28.35"}]}]},{"title":"Diarrhoea: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"25.59"}]}]},{"title":"Diarrhoea: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"26.43"}]}]},{"title":"Diarrhoea: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Diarrhoea: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.52","spread":"16.27"}]}]},{"title":"Diarrhoea: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"47.14"}]}]},{"title":"Diarrhoea: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Diarrhoea: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.31","spread":"28.15"}]}]},{"title":"Financial difficulties: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.80","spread":"33.24"}]}]},{"title":"Financial difficulties: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.60","spread":"21.66"}]}]},{"title":"Financial difficulties: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.32","spread":"23.39"}]}]},{"title":"Financial difficulties: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.76","spread":"21.52"}]}]},{"title":"Financial difficulties: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.44","spread":"26.24"}]}]},{"title":"Financial difficulties: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Financial difficulties: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.84","spread":"23.17"}]}]},{"title":"Financial difficulties: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Financial difficulties: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"27.79"}]}]},{"title":"Financial difficulties: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Financial difficulties: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.48","spread":"20.81"}]}]},{"title":"Financial difficulties: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"16.67"}]}]},{"title":"Financial difficulties: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.08","spread":"23.61"}]}]},{"title":"Financial difficulties: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Financial difficulties: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.15","spread":"27.13"}]}]},{"title":"Financial difficulties: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"14.91"}]}]},{"title":"Financial difficulties: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"22.06"}]}]},{"title":"Financial difficulties: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Financial difficulties: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"28.16"}]}]},{"title":"Financial difficulties: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"16.67"}]}]},{"title":"Financial difficulties: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.80","spread":"25.92"}]}]},{"title":"Financial difficulties: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Financial difficulties: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"34.96"}]}]},{"title":"Financial difficulties: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Financial difficulties: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.82","spread":"34.80"}]}]},{"title":"Financial difficulties: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Financial difficulties: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","spread":"21.36"}]}]},{"title":"Financial difficulties: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Financial difficulties: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"38.49"}]}]},{"title":"Financial difficulties: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Financial difficulties: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"32.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II","description":"EORTC QLQ-LC13 consisted of 13 questions for dyspnea (3 items) and 10 single items (cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm/shoulder, other pain). Questions used 4-point scale (1 'Not at all' to 4 'Very much'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below represents absolute data at baseline.","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)","groups":[{"id":"OG000","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"classes":[{"title":"Dyspnoea: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.85","spread":"27.13"}]}]},{"title":"Dyspnoea: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.24","spread":"22.57"}]}]},{"title":"Dyspnoea: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.64","spread":"20.65"}]}]},{"title":"Dyspnoea: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.35","spread":"21.67"}]}]},{"title":"Dyspnoea: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.41","spread":"21.68"}]}]},{"title":"Dyspnoea: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"7.86"}]}]},{"title":"Dyspnoea: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.09","spread":"20.41"}]}]},{"title":"Dyspnoea: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"11.11"}]}]},{"title":"Dyspnoea: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.41","spread":"21.69"}]}]},{"title":"Dyspnoea: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"7.86"}]}]},{"title":"Dyspnoea: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.64","spread":"20.25"}]}]},{"title":"Dyspnoea: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"27.78"}]}]},{"title":"Dyspnoea: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.74","spread":"24.77"}]}]},{"title":"Dyspnoea: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-27.78","spread":"23.57"}]}]},{"title":"Dyspnoea: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.02","spread":"19.63"}]}]},{"title":"Dyspnoea: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"16.48"}]}]},{"title":"Dyspnoea: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.28","spread":"19.54"}]}]},{"title":"Dyspnoea: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"16.97"}]}]},{"title":"Dyspnoea: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.22","spread":"25.27"}]}]},{"title":"Dyspnoea: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.89","spread":"29.22"}]}]},{"title":"Dyspnoea: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.76","spread":"26.96"}]}]},{"title":"Dyspnoea: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"7.86"}]}]},{"title":"Dyspnoea: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.19","spread":"22.48"}]}]},{"title":"Dyspnoea: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"7.86"}]}]},{"title":"Dyspnoea: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.40","spread":"16.26"}]}]},{"title":"Dyspnoea: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":"23.13"}]}]},{"title":"Dyspnoea: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"17.82"}]}]},{"title":"Dyspnoea: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"0.00"}]}]},{"title":"Dyspnoea: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-51.85","spread":"23.13"}]}]},{"title":"Dyspnoea: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11"}]}]},{"title":"Dyspnoea: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dyspnoea: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.44","spread":"23.45"}]}]},{"title":"Coughing: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.76","spread":"27.47"}]}]},{"title":"Coughing: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.89","spread":"31.47"}]}]},{"title":"Coughing: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.82","spread":"27.34"}]}]},{"title":"Coughing: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.61","spread":"24.46"}]}]},{"title":"Coughing: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.17","spread":"31.11"}]}]},{"title":"Coughing: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Coughing: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"24.44"}]}]},{"title":"Coughing: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.22","spread":"19.25"}]}]},{"title":"Coughing: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.77","spread":"28.67"}]}]},{"title":"Coughing: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-50.00","spread":"23.57"}]}]},{"title":"Coughing: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"27.01"}]}]},{"title":"Coughing: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"50.00"}]}]},{"title":"Coughing: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.04","spread":"35.12"}]}]},{"title":"Coughing: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"0.00"}]}]},{"title":"Coughing: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"25.40"}]}]},{"title":"Coughing: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.00","spread":"29.81"}]}]},{"title":"Coughing: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"29.45"}]}]},{"title":"Coughing: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Coughing: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"27.80"}]}]},{"title":"Coughing: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-25.00","spread":"31.91"}]}]},{"title":"Coughing: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.25","spread":"28.35"}]}]},{"title":"Coughing: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Coughing: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"35.21"}]}]},{"title":"Coughing: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Coughing: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.38","spread":"29.24"}]}]},{"title":"Coughing: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Coughing: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"29.55"}]}]},{"title":"Coughing: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Coughing: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-44.44","spread":"19.25"}]}]},{"title":"Coughing: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Coughing: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.48","spread":"32.87"}]}]},{"title":"Hemoptysis: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"6.41"}]}]},{"title":"Hemoptysis: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"6.03"}]}]},{"title":"Hemoptysis: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"6.47"}]}]},{"title":"Hemoptysis: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"6.66"}]}]},{"title":"Hemoptysis: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"7.36"}]}]},{"title":"Hemoptysis: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"13.25"}]}]},{"title":"Hemoptysis: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"7.54"}]}]},{"title":"Hemoptysis: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"7.97"}]}]},{"title":"Hemoptysis: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"5.80"}]}]},{"title":"Hemoptysis: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"10.48"}]}]},{"title":"Hemoptysis: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"6.19"}]}]},{"title":"Hemoptysis: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"6.54"}]}]},{"title":"Hemoptysis: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"22.28"}]}]},{"title":"Hemoptysis: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"7.45"}]}]},{"title":"Hemoptysis: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"9.25"}]}]},{"title":"Hemoptysis: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Hemoptysis: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Hemoptysis: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"7.80"}]}]},{"title":"Sore mouth: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.06","spread":"16.09"}]}]},{"title":"Sore mouth: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"13.68"}]}]},{"title":"Sore mouth: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"13.99"}]}]},{"title":"Sore mouth: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"17.22"}]}]},{"title":"Sore mouth: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":"17.91"}]}]},{"title":"Sore mouth: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":"11.81"}]}]},{"title":"Sore mouth: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"38.49"}]}]},{"title":"Sore mouth: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"15.40"}]}]},{"title":"Sore mouth: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Sore mouth: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"9.71"}]}]},{"title":"Sore mouth: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.07","spread":"26.03"}]}]},{"title":"Sore mouth: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"13.56"}]}]},{"title":"Sore mouth: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"23.57"}]}]},{"title":"Sore mouth: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"14.04"}]}]},{"title":"Sore mouth: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"13.07"}]}]},{"title":"Sore mouth: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.55","spread":"18.67"}]}]},{"title":"Sore mouth: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"7.45"}]}]},{"title":"Sore mouth: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"11.79"}]}]},{"title":"Sore mouth: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Sore mouth: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Sore mouth: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Sore mouth: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"15.21"}]}]},{"title":"Dysphagia: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.64","spread":"11.61"}]}]},{"title":"Dysphagia: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"11.36"}]}]},{"title":"Dysphagia: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"10.42"}]}]},{"title":"Dysphagia: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"11.70"}]}]},{"title":"Dysphagia: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"11.91"}]}]},{"title":"Dysphagia: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Dysphagia: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"14.90"}]}]},{"title":"Dysphagia: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Dysphagia: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"5.41"}]}]},{"title":"Dysphagia: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Dysphagia: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"12.56"}]}]},{"title":"Dysphagia: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"27.22"}]}]},{"title":"Dysphagia: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"16.54"}]}]},{"title":"Dysphagia: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Dysphagia: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"13.56"}]}]},{"title":"Dysphagia: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"27.89"}]}]},{"title":"Dysphagia: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.57","spread":"13.88"}]}]},{"title":"Dysphagia: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Dysphagia: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"14.85"}]}]},{"title":"Dysphagia: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"15.82"}]}]},{"title":"Dysphagia: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"10.81"}]}]},{"title":"Dysphagia: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":"9.25"}]}]},{"title":"Dysphagia: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Dysphagia: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Dysphagia: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":"17.35"}]}]},{"title":"Peripheral neuropathy: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.08","spread":"22.28"}]}]},{"title":"Peripheral neuropathy: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":"17.88"}]}]},{"title":"Peripheral neuropathy: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"20.83"}]}]},{"title":"Peripheral neuropathy: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"22.40"}]}]},{"title":"Peripheral neuropathy: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"20.24"}]}]},{"title":"Peripheral neuropathy: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Peripheral neuropathy: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":"24.40"}]}]},{"title":"Peripheral neuropathy: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.25"}]}]},{"title":"Peripheral neuropathy: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"18.98"}]}]},{"title":"Peripheral neuropathy: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"21.00"}]}]},{"title":"Peripheral neuropathy: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"16.67"}]}]},{"title":"Peripheral neuropathy: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"23.48"}]}]},{"title":"Peripheral neuropathy: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"26.41"}]}]},{"title":"Peripheral neuropathy: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"27.89"}]}]},{"title":"Peripheral neuropathy: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"23.45"}]}]},{"title":"Peripheral neuropathy: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"24.00"}]}]},{"title":"Peripheral neuropathy: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"28.27"}]}]},{"title":"Peripheral neuropathy: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"21.36"}]}]},{"title":"Peripheral neuropathy: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.82","spread":"37.36"}]}]},{"title":"Peripheral neuropathy: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"17.82"}]}]},{"title":"Peripheral neuropathy: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.56","spread":"38.49"}]}]},{"title":"Peripheral neuropathy: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Peripheral neuropathy: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"22.52"}]}]},{"title":"Alopecia: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.69","spread":"25.80"}]}]},{"title":"Alopecia: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":"22.29"}]}]},{"title":"Alopecia: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"31.24"}]}]},{"title":"Alopecia: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.96","spread":"25.04"}]}]},{"title":"Alopecia: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"27.98"}]}]},{"title":"Alopecia: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.51","spread":"27.72"}]}]},{"title":"Alopecia: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"32.85"}]}]},{"title":"Alopecia: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"20.12"}]}]},{"title":"Alopecia: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.21","spread":"22.58"}]}]},{"title":"Alopecia: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.45","spread":"15.91"}]}]},{"title":"Alopecia: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"14.91"}]}]},{"title":"Alopecia: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.60","spread":"19.36"}]}]},{"title":"Alopecia: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Alopecia: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.67","spread":"27.08"}]}]},{"title":"Alopecia: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"16.67"}]}]},{"title":"Alopecia: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.03","spread":"33.98"}]}]},{"title":"Alopecia: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"26.21"}]}]},{"title":"Alopecia: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Alopecia: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"25.32"}]}]},{"title":"Alopecia: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Alopecia: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"21.36"}]}]},{"title":"Alopecia: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Alopecia: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Alopecia: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":"27.97"}]}]},{"title":"Pain in chest: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.52","spread":"28.26"}]}]},{"title":"Pain in chest: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"29.75"}]}]},{"title":"Pain in chest: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.54","spread":"23.69"}]}]},{"title":"Pain in chest: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.84","spread":"27.87"}]}]},{"title":"Pain in chest: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"23.57"}]}]},{"title":"Pain in chest: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in chest: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.42","spread":"22.68"}]}]},{"title":"Pain in chest: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Pain in chest: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"26.68"}]}]},{"title":"Pain in chest: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in chest: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.48","spread":"19.22"}]}]},{"title":"Pain in chest: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"41.94"}]}]},{"title":"Pain in chest: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.06","spread":"19.46"}]}]},{"title":"Pain in chest: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"0.00"}]}]},{"title":"Pain in chest: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.30","spread":"20.62"}]}]},{"title":"Pain in chest: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.33","spread":"38.01"}]}]},{"title":"Pain in chest: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.45","spread":"16.29"}]}]},{"title":"Pain in chest: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in chest: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"18.67"}]}]},{"title":"Pain in chest: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-25.00","spread":"31.91"}]}]},{"title":"Pain in chest: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.90","spread":"28.27"}]}]},{"title":"Pain in chest: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in chest: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"18.73"}]}]},{"title":"Pain in chest: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in chest: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"22.96"}]}]},{"title":"Pain in chest: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"19.25"}]}]},{"title":"Pain in chest: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.50","spread":"24.80"}]}]},{"title":"Pain in chest: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"}]}]},{"title":"Pain in chest: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.22","spread":"19.25"}]}]},{"title":"Pain in chest: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in chest: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.80","spread":"26.83"}]}]},{"title":"Pain in arm or shoulder: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.88","spread":"28.18"}]}]},{"title":"Pain in arm or shoulder: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.22","spread":"25.37"}]}]},{"title":"Pain in arm or shoulder: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.77","spread":"30.05"}]}]},{"title":"Pain in arm or shoulder: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.86","spread":"24.78"}]}]},{"title":"Pain in arm or shoulder: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.83","spread":"27.62"}]}]},{"title":"Pain in arm or shoulder: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in arm or shoulder: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.42","spread":"23.93"}]}]},{"title":"Pain in arm or shoulder: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"38.49"}]}]},{"title":"Pain in arm or shoulder: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.26","spread":"33.36"}]}]},{"title":"Pain in arm or shoulder: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in arm or shoulder: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":"25.82"}]}]},{"title":"Pain in arm or shoulder: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.06","spread":"21.17"}]}]},{"title":"Pain in arm or shoulder: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in arm or shoulder: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"25.07"}]}]},{"title":"Pain in arm or shoulder: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"23.57"}]}]},{"title":"Pain in arm or shoulder: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"26.62"}]}]},{"title":"Pain in arm or shoulder: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.85","spread":"27.21"}]}]},{"title":"Pain in arm or shoulder: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"33.33"}]}]},{"title":"Pain in arm or shoulder: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.35","spread":"28.96"}]}]},{"title":"Pain in arm or shoulder: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.77","spread":"24.45"}]}]},{"title":"Pain in arm or shoulder: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.69","spread":"38.86"}]}]},{"title":"Pain in arm or shoulder: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"21.36"}]}]},{"title":"Pain in arm or shoulder: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Pain in arm or shoulder: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in arm or shoulder: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"29.92"}]}]},{"title":"Pain in other parts: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.00","spread":"36.42"}]}]},{"title":"Pain in other parts: Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.96","spread":"42.78"}]}]},{"title":"Pain in other parts: Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.59","spread":"41.70"}]}]},{"title":"Pain in other parts: Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-19.26","spread":"41.74"}]}]},{"title":"Pain in other parts: Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-19.30","spread":"36.87"}]}]},{"title":"Pain in other parts: Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"title":"Pain in other parts: Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-18.52","spread":"37.75"}]}]},{"title":"Pain in other parts: Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"33.33"}]}]},{"title":"Pain in other parts: Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-18.52","spread":"36.90"}]}]},{"title":"Pain in other parts: Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"94.28"}]}]},{"title":"Pain in other parts: Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.16","spread":"37.38"}]}]},{"title":"Pain in other parts: Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"56.93"}]}]},{"title":"Pain in other parts: Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.22","spread":"34.45"}]}]},{"title":"Pain in other parts: Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"47.14"}]}]},{"title":"Pain in other parts: Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.94","spread":"38.41"}]}]},{"title":"Pain in other parts: Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.33","spread":"38.01"}]}]},{"title":"Pain in other parts: Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.38","spread":"34.29"}]}]},{"title":"Pain in other parts: Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-44.44","spread":"38.49"}]}]},{"title":"Pain in other parts: Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.61","spread":"39.02"}]}]},{"title":"Pain in other parts: Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"41.94"}]}]},{"title":"Pain in other parts: Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.00","spread":"33.29"}]}]},{"title":"Pain in other parts: Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in other parts: Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.26","spread":"27.81"}]}]},{"title":"Pain in other parts: Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"23.57"}]}]},{"title":"Pain in other parts: Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.12","spread":"22.47"}]}]},{"title":"Pain in other parts: Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.22","spread":"38.49"}]}]},{"title":"Pain in other parts: Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"36.51"}]}]},{"title":"Pain in other parts: Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"47.14"}]}]},{"title":"Pain in other parts: Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33"}]}]},{"title":"Pain in other parts: Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}]},{"title":"Pain in other parts: Last visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.56","spread":"37.96"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline to up to 28 days after the last dose of alectinib (up to 284 weeks)","description":"Safety population","eventGroups":[{"id":"EG000","title":"Alectinib 300 mg (Fasted): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","deathsNumAffected":7,"deathsNumAtRisk":7,"seriousNumAffected":1,"seriousNumAtRisk":7,"otherNumAffected":7,"otherNumAtRisk":7},{"id":"EG001","title":"Alectinib 460 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","deathsNumAffected":4,"deathsNumAtRisk":7,"seriousNumAffected":2,"seriousNumAtRisk":7,"otherNumAffected":7,"otherNumAtRisk":7},{"id":"EG002","title":"Alectinib 600 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","deathsNumAffected":6,"deathsNumAtRisk":13,"seriousNumAffected":6,"seriousNumAtRisk":13,"otherNumAffected":12,"otherNumAtRisk":13},{"id":"EG003","title":"Alectinib 760 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","deathsNumAffected":2,"deathsNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":7,"otherNumAtRisk":7},{"id":"EG004","title":"Alectinib 900 mg (Fed): Phase I","description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","deathsNumAffected":9,"deathsNumAtRisk":13,"seriousNumAffected":1,"seriousNumAtRisk":13,"otherNumAffected":13,"otherNumAtRisk":13},{"id":"EG005","title":"Alectinib 600 mg (Fed): Phase II","description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","deathsNumAffected":45,"deathsNumAtRisk":87,"seriousNumAffected":21,"seriousNumAtRisk":87,"otherNumAffected":85,"otherNumAtRisk":87}],"seriousEvents":[{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Chronic myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Cerebral ventricle dilatation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Hyperammonaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Radiation necrosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Stroke-like migraine attacks after radiation therapy","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Tumour necrosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Hypercapnia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":87}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":7},{"groupId":"EG001","numAffected":3,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":5,"numAtRisk":7},{"groupId":"EG004","numAffected":7,"numAtRisk":13},{"groupId":"EG005","numAffected":36,"numAtRisk":87}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":3,"numAtRisk":13},{"groupId":"EG005","numAffected":22,"numAtRisk":87}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":9,"numAtRisk":87}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":4,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":3,"numAtRisk":7},{"groupId":"EG004","numAffected":2,"numAtRisk":13},{"groupId":"EG005","numAffected":23,"numAtRisk":87}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":12,"numAtRisk":87}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":5,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":12,"numAtRisk":87}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":3,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":7,"numAtRisk":87}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Myopathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":4,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":4,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":20,"numAtRisk":87}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":3,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":16,"numAtRisk":87}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":3,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":18,"numAtRisk":87}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":2,"numAtRisk":13},{"groupId":"EG005","numAffected":10,"numAtRisk":87}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":4,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":12,"numAtRisk":87}]},{"term":"Electrocardiogram PR Prolongation","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":8,"numAtRisk":87}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Blood phosphorus increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Heart rate irregular","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Neutrophil count","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":17,"numAtRisk":87}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":3,"numAtRisk":7},{"groupId":"EG004","numAffected":3,"numAtRisk":13},{"groupId":"EG005","numAffected":34,"numAtRisk":87}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":3,"numAtRisk":13},{"groupId":"EG005","numAffected":22,"numAtRisk":87}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":3,"numAtRisk":13},{"groupId":"EG005","numAffected":21,"numAtRisk":87}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":14,"numAtRisk":87}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":2,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Oral disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":4,"numAtRisk":13},{"groupId":"EG005","numAffected":25,"numAtRisk":87}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":8,"numAtRisk":87}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":12,"numAtRisk":87}]},{"term":"Burning sensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":2,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":8,"numAtRisk":87}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Aura","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Narcolepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":14,"numAtRisk":87}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":2,"numAtRisk":13},{"groupId":"EG005","numAffected":9,"numAtRisk":87}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":3,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":3,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":3,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":13,"numAtRisk":87}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":3,"numAtRisk":13},{"groupId":"EG005","numAffected":10,"numAtRisk":87}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":9,"numAtRisk":87}]},{"term":"Fluid retention","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dyslipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":7},{"groupId":"EG001","numAffected":4,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":3,"numAtRisk":13},{"groupId":"EG005","numAffected":19,"numAtRisk":87}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":3,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":18,"numAtRisk":87}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Paranasal sinus discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Upper respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":3,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":8,"numAtRisk":87}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":10,"numAtRisk":87}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":7,"numAtRisk":87}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":3,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":4,"numAtRisk":13},{"groupId":"EG005","numAffected":17,"numAtRisk":87}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":4,"numAtRisk":13},{"groupId":"EG003","numAffected":2,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":6,"numAtRisk":87}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":8,"numAtRisk":87}]},{"term":"Bundle branch block left","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Diastolic dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":13,"numAtRisk":87}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Eye irritation","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Periorbital oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":7,"numAtRisk":87}]},{"term":"Vitreous floaters","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":5,"numAtRisk":87}]},{"term":"Post lumbar puncture syndrome","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Radiation injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":2,"numAtRisk":7},{"groupId":"EG002","numAffected":2,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":2,"numAtRisk":13},{"groupId":"EG005","numAffected":7,"numAtRisk":87}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Tanning","organSystem":"Social circumstances","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Gingival swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Noninfective gingivitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Babesiosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Onychomycosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Blood testosterone decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Electrocardiogram abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hyperphosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":1,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypertonic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":1,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":0,"numAtRisk":7},{"groupId":"EG004","numAffected":1,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]},{"term":"Sinus pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 20.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":7},{"groupId":"EG002","numAffected":0,"numAtRisk":13},{"groupId":"EG003","numAffected":1,"numAtRisk":7},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":87}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582670","term":"alectinib"}]}},"hasResults":true}